The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease
Open accessAbstract
VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC 50 ] = 354 nM) and in human fetal hepatocytes infected with genotype 1a HCV-positive patient sera (IC 50 = 280 nM). VX-950 forms a covalent but reversible complex with the genotype 1a HCV NS3-4A protease in a slow-on, slow-off process with a steady-state inhibition constant ( K i *) of 7 nM. Dissociation of the covalent enzyme-inhibitor complex of VX-950 and genotype 1a HCV protease has a half-life of almost an hour. A >4-log 10 reduction in the HCV RNA levels was observed after a 2-week incubation of replicon cells with VX-950, with no rebound of viral RNA observed after withdrawal of the inhibitor. In several animal species, VX-950 exhibits a favorable pharmacokinetic profile with high exposure in the liver. In a recently developed HCV protease mouse model, VX-950 showed excellent inhibition of HCV NS3-4A protease activity in the liver. Therefore, the overall preclinical profile of VX-950 supports its candidacy as a novel oral therapy against hepatitis C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., & Bartenschlager, R. (1999) · Science · doi:10.1126/science.285.5424.110 · Cited by 2,814
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J., & Perelson, A. S. (1998) · Science · doi:10.1126/science.282.5386.103 · Cited by 2,113
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends
Wasley, A., & Alter, M. J. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9506 · Cited by 979
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
Lamarre, D., Anderson, P. C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bös, M., Cameron, D. R., Cartier, M., Cordingley, M. G., et al. (2003) · Nature · doi:10.1038/nature02099 · Cited by 917
The Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 814
Kim, J. L., Morgenstern, K. A., Lin, C., Fox, T., Dwyer, M. D., Landro, J. A., Chambers, S. P., Markland, W., Lepre, C. A., O'Malley, E. T., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81351-3 · Cited by 727
Self-citationGrakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M., & Rice, C. M. (1993) · Journal of Virology · doi:10.1128/jvi.67.5.2832-2843.1993 · Cited by 610
Kolykhalov, A. A., Mihalik, K., Feinstone, S. M., & Rice, C. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.2046-2051.2000 · Cited by 606
Atala, A., & Lanza, R. (2002) · Cited by 533
Hepatitis C: an epidemiological review
Memon, M. I., & Memon, M. A. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00329.x · Cited by 293
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313020200 · Cited by 288
Self-citationLin, C., Thomson, J. A., & Rice, C. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.7.4373-4380.1995 · Cited by 221
Self-citationDe Francesco, R., Tomei, L., Altamura, S., Summa, V., & Migliaccio, G. (2003) · Antiviral Research · doi:10.1016/s0166-3542(03)00028-7 · Cited by 186
Inhibition of the Hepatitis C Virus NS3/4A Protease
Marco, S. D., Rizzi, M., Volpari, C., Walsh, M. A., Narjes, F., Colarusso, S., Francesco, R. D., Matassa, V. G., & Sollazzo, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7152 · Cited by 127
Castet, V., Fournier, C., Soulier, A., Brillet, R., Coste, J., Larrey, D. G., Dhumeaux, D., Maurel, P., & Pawlotsky, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.8189-8199.2002 · Cited by 120
Iacovacci, S., Manzin, A., Barca, S., Sargiacomo, M., Serafino, A., Valli, M. B., Macioce, G., Hassan, H. J., Ponzetto, A., Clementi, M., et al. (1997) · Hepatology · doi:10.1002/hep.510260535 · Cited by 105
Thibeault, D., Bousquet, C., Gingras, R., Lagacé, L., Maurice, R., White, P. W., & Lamarre, D. (2004) · Journal of Virology · doi:10.1128/jvi.78.14.7352-7359.2004 · Cited by 84
Lin, K. W., Kwong, A. D., & Lin, C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4784-4792.2004 · Cited by 79
Self-citationYip, Y. Y., Victor, F., Lamar, J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.074 · Cited by 64
Liver Cell Culture and Lineage Biology
Macdonald, J., Xu, A. S. L., Kubota, H., Liu, H., Moss, N., Lodestro, C., Luntz, T., Lecluyse, E., Hamilton, G., Rong, Y.-W., et al. (2002) · Elsevier eBooks · doi:10.1016/b978-012436636-7/50126-9 · Cited by 22
Cited by
The exploration of macrocycles for drug discovery — an underexploited structural class
Driggers, E. M., Hale, S. P., Lee, J., & Terrett, N. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2590 · Cited by 1,370
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourlière, M., Gharakhanian, S., Bengtsson, L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807650 · Cited by 1,025
Self-citationPROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Self-citationMacrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
Giordanetto, F., & Kihlberg, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400887j · Cited by 563
Metadata
- Authors
- Perni, R. B., Almquist, S. J., Byrn, R. A., Chandorkar, G., Chaturvedi, P. R., Courtney, L. F., Decker, C. J., Dinehart, K., Gates, C. A., Harbeson, S. L., Heiser, A., Kalkeri, G., Kolaczkowski, E., Lin, K., Luong, Y.-P., Rao, B. G., Taylor, W. P., Thomson, J. A., Tung, R. D., Wei, Y., Kwong, A. D., & Lin, C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-03
- Volume
- 50
- Issue
- 3
- Pages
- 899-909
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2140369033
- Cited by
- 386
- References
- 26
- FWCI
- 19.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.